| abstract |
Long-acting formulations comprising isopropyl (( S )-(((( R )-l-(6-amino-9 H -purin-9- yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)- L -alaninate, or a pharmaceutically acceptable salt thereof, and a biodegradable polymer, e.g. poly(lactic-co-glycolic acid) (PLGA), are described, as are methods of making the long acting formulations and uses thereof. |